{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:44:42Z","timestamp":1777934682190,"version":"3.51.4"},"reference-count":24,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In acute lymphoblastic leukemia (ALL), pegaspargase is included in the backbone of numerous chemotherapy regimens. Treatment-related toxicities can be substantial, often resulting in treatment delays, dose reductions, or early discontinuation. This study aimed to evaluate whether differences in efficacy, safety, and economic outcomes exist between standard dosing and modified approaches involving dose-reduced and delayed administration of pegaspargase.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective, single-center study evaluated hospitalized adult patients who received pegaspargase as part of CALGB 10403 induction course I. Patients were stratified into two groups: 1) full pegaspargase dose 2500 units\/m\n                      <jats:sup>2<\/jats:sup>\n                      and standard administration on day 4 (Early PEG group), or 2) dose reduced pegaspargase 1000 units\/m\n                      <jats:sup>2<\/jats:sup>\n                      and delayed administration on day 15 (Delayed PEG group).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eight patients (27%) were treated with a reduced dose of pegaspargase on day 15 of induction (Delayed PEG). Median age of the study population was 27 years, and median BMI was 29.6\u2005kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      . The majority of patients were male (60%), Hispanic (53%), and had a diagnosis of Philadelphia chromosome negative B-ALL (70%). Incidence of grade 3 or higher toxicities was not significantly different between groups. MRD status at the end of induction was similar between groups [Early PEG 12 (55%) vs Delayed PEG 4 (50%), p\u2009=\u20090.51]. Economic outcomes within 30 days were also similar.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study demonstrates comparable incidence of high-grade toxicities and MRD negative status, suggesting that concomitant dose reduction and delay of pegaspargase administration during CALGB 10403 induction does not significantly impact effectiveness, safety, or economic outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552251388384","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T17:40:40Z","timestamp":1761846040000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the clinical and economic impact of delayed versus early pegaspargase"],"prefix":"10.1177","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8570-3224","authenticated-orcid":false,"given":"Scott","family":"Vo","sequence":"first","affiliation":[{"name":"University of California San Diego Health (UCSDH)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8781-962X","authenticated-orcid":false,"given":"Janine","family":"Martino","sequence":"additional","affiliation":[{"name":"University of California San Diego Health (UCSDH)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Medley","sequence":"additional","affiliation":[{"name":"University of California San Diego Health (UCSDH)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0921-549X","authenticated-orcid":false,"given":"Nimish","family":"Patel","sequence":"additional","affiliation":[{"name":"UC San Diego Skaggs School of Pharmacy & Pharmaceutical Sciences"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiffany N","family":"Tanaka","sequence":"additional","affiliation":[{"name":"UCSDH"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasmine","family":"Anouty","sequence":"additional","affiliation":[{"name":"University of California San Diego Health (UCSDH)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.4103\/0976-500X.184769"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2014.1003056"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2021.100908"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.08.009"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03692"},{"key":"e_1_3_3_7_2","unstructured":"National Comprehensive Cancer Network. Acute Lymphoblastic Leukemia (Version 2.2024). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf. (Accessed September 7 2024)."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-881961"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.224"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-019-09971-2"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007791"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552241246104"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19880"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312948"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2014.08.037"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v12.i8.506"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231202217"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2019.1680839"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000858"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002132"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1312384"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27041"},{"key":"e_1_3_3_23_2","unstructured":"Kaiser Family Foundation. Hospital Expenses per Adjusted Inpatient Day by Ownership Type. KFF. https:\/\/www.kff.org\/health-costs\/state-indicator\/expenses-per-inpatient-day-by-ownership\/?currentTimeframe=0&sortModel=%7B%22colId%22:%22Location%22 %22sort%22:%22asc%22%7D (Accessed June 8 2025)."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1397658"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2023.2233412"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251388384","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552251388384","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552251388384","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:31:55Z","timestamp":1777689115000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552251388384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":24,"alternative-id":["10.1177\/10781552251388384"],"URL":"https:\/\/doi.org\/10.1177\/10781552251388384","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"article-number":"10781552251388384"}}